Analytical Data
-
Gene name
PSCA
- Application
-
Alternative Names
PSCA; UNQ206; PRO232
-
Species
Mouse
-
Source
HEK293
-
Tag
C-Avi;C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P57096
-
Expression Region
L21-N95
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
The PSCA (prostate stem cell antigen) is a glycoprotein primarily expressed in prostate tissues and is implicated in various cancers, particularly prostate cancer. Its overexpression in malignant cells makes it a promising target for diagnostic and therapeutic strategies. Research into PSCA has gained significant momentum due to its potential role in tumorigenesis and cancer progression. The protein is believed to play a role in cell adhesion and signaling processes that are crucial for tumor growth and metastasis. As an ideal candidate for cancer immunotherapy, PSCA has been the focus of various studies aimed at developing monoclonal antibodies and vaccine-based treatments. Moreover, PSCA's limited expression in normal tissues, along with its elevated presence in cancerous cells, has led to increased interest in its utility as a biomarker for early diagnosis and targeted therapies. Understanding the structure and function of PSCA through the development of recombinant proteins is essential for elucidating its biological role and enhancing therapeutic applications. This ongoing research aims to explore PSCA's mechanisms of action, interactions with other cellular components, and its potential as a target for innovative cancer treatments.
